Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Baxter International executive Julie Foster, President of Front Line Care, filed an initial ownership report showing both stock and option holdings. She directly holds 31,248 shares of common stock and a stock option covering 25,862 shares at an exercise price of $20.37 per share, expiring on February 27, 2036. The options become exercisable in three equal annual installments beginning on March 1, 2027, the first anniversary of the grant date.
Baxter International executive Steven P. Wallace, President of Advanced Surgery, reported his initial holdings on a Form 3. He directly owns 70,282 shares of common stock and holds several stock option awards covering additional shares at exercise prices between $20.37 and $74.47 with expirations from 2032 through 2036.
Baxter International Inc. executive James Teaff filed an initial Form 3 reporting his ownership of company securities. He reports direct ownership of 31,120 shares of Baxter common stock. The filing also lists several stock option awards, each giving the right to buy Baxter common shares at set exercise prices before future expiration dates.
These options cover blocks of shares at exercise prices ranging from $20.37 to $85.23 per share, with expiration dates between 2027 and 2036. Footnotes explain that the options generally become exercisable in three equal annual installments starting on the first anniversary of their respective grant dates. The filing records current holdings and does not reflect new open-market purchases or sales.
The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Baxter International Inc. common stock, representing 0% of the class after an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in accordance with SEC Release No. 34-39538, effective with the reorganization described, and that The Vanguard Group, Inc. no longer is deemed to beneficially own securities held by those subsidiaries. The amendment is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
Baxter International Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 5, 2026 on five items: electing nine directors, an advisory say-on-pay for 2025, ratifying PricewaterhouseCoopers as auditor, approving a Second Amended and Restated 2021 Incentive Plan, and amending its charter to lower the Board’s minimum size from nine to seven directors.
The company highlights completion of the Kidney Care business sale to Carlyle for about $3.3 billion of net after-tax proceeds, launch of new monitoring and communications products, and recovery of its North Cove facility after Hurricane Helene. Baxter reports 2025 continuing-operations net sales of $11.2 billion, Adjusted EPS of $2.27, GAAP EPS of ($1.75), operating cash flow of $951 million and free cash flow of $438 million, all used in its pay-for-performance programs.
Governance changes include appointing Andrew Hider as President and CEO in August 2025, separating the Chair and CEO roles with Brent Shafer as Non-Executive Chair, adding director Michael McDonnell, refreshing committee leadership, and maintaining strong stockholder rights, board independence and extensive investor engagement.
Baxter International Inc. provides a spring 2026 stockholder engagement update outlining leadership changes, 2025 performance, capital allocation priorities, and governance and sustainability initiatives. The company highlights the August 2025 appointment of Andrew Hider as President and CEO and the separation of the Chair and CEO roles, with Brent Shafer serving as Non-Executive Chair.
Baxter reports 2025 revenue from continuing operations of $11.2B with +3% operational sales growth, a +20 basis point increase in adjusted operating margin, and a +20% rise in adjusted diluted EPS. Baxter targets net leverage of about 3.0x by the end of 2026, prioritizing debt repayment while maintaining a quarterly dividend of $0.01 per share and selectively investing in capex, R&D, and tuck-in M&A.
The presentation emphasizes board refreshment, noting three new independent directors over the last three years, including Michael McDonnell joining the Board and Audit Committee in February 2026. Baxter also describes extensive 2025 outreach, contacting stockholders holding roughly 68% of shares and engaging with holders of about 61% to inform governance, compensation design, and refreshed sustainability commitments based on a 2025 double materiality assessment.
Baxter International Inc. announced a chief financial officer transition. As of the transition date, Joel Grade’s service as executive vice president and CFO ended, and he moved into a non-executive advisory role through April 30, 2026. Subject to a separation agreement, he will receive severance benefits under Baxter’s Executive Severance Plan for Group 1 Executives. The company stated his transition was not due to any disagreement with management or the board.
Effective the same date, Baxter’s board appointed Anita Zielinski, senior vice president, chief accounting officer and controller, as interim CFO. She will retain her existing responsibilities and receive additional compensation of $50,000 per month while serving as interim CFO, plus a one-time restricted stock unit award valued at $250,000, scheduled to vest on the third anniversary of the grant date. Baxter also reiterated its full-year 2026 financial outlook previously provided on February 12, 2026.
Baxter International Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held on May 5, 2026. The proxy highlights governance and succession actions during a corporate transition, including the appointment of Andrew P. Hider as President and CEO in August 2025 and completion of strategic actions.
The company completed the sale of its Kidney Care business to Carlyle Group on January 31, 2025, generating approximately $3.3 billion of net after‑tax proceeds. The filing describes operational recovery from Hurricane Helene with North Cove IV production and inventory restored by May 2025. Proposals include election of nine directors, an advisory vote on 2025 executive pay, ratification of PricewaterhouseCoopers LLP, approval of an amended 2021 Incentive Plan and an amendment to reduce the Board minimum to five directors.
Baxter International senior vice president and chief accounting officer Anita A. Zielinski reported a routine tax-withholding transaction related to equity compensation. On March 6, 2026, 1,932 shares of common stock at $17.69 per share were forfeited to cover taxes from vested restricted stock units granted on March 6, 2025. After this withholding, she directly holds 46,281 Baxter shares.